Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Sex-linked Disorders01:43

Sex-linked Disorders

93.7K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
93.7K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

16
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same author

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD-Related Myelopathy.

Annals of clinical and translational neurology·2026
Same author

Machine Learning-Assisted Quantification of Organelle Abundance.

Bio-protocol·2026
Same author

The Grey Zone Project: Risk-Based Classification of ABCD1 Variants in X-Linked Adrenoleukodystrophy.

Journal of inherited metabolic disease·2026
Same author

Use of Brain MRI in Cerebral Adrenoleukodystrophy: International Recommendations for Screening, Monitoring, and Research.

Neurology·2026
Same author

Neurocognitive Outcome After Pediatric Traumatic Brain Injury: Patient Subgroups With Diverging Outcome.

Pediatric neurology·2026

Related Experiment Video

Updated: Apr 25, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

7.5K

X-linked adrenoleukodystrophy: pathogenesis and treatment.

Marc Engelen1, Stephan Kemp, Bwee-Tien Poll-The

  • 1Department of Pediatric Neurology/Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, 1100 DD, The Netherlands, m.engelen@amc.uva.nl.

Current Neurology and Neuroscience Reports
|August 14, 2014
PubMed
Summary

X-linked adrenoleukodystrophy (X-ALD) involves ABCD1 gene mutations, leading to very long chain fatty acid accumulation. This review simplifies X-ALD classification and discusses unresolved mechanisms and treatments.

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K

Related Experiment Videos

Last Updated: Apr 25, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

7.5K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • X-linked adrenoleukodystrophy (X-ALD) is a rare genetic metabolic disorder.
  • It is characterized by mutations in the ABCD1 gene, leading to very long-chain fatty acid accumulation.
  • X-ALD presents a wide range of clinical symptoms, affecting males and females differently.

Purpose of the Study:

  • To propose a simplified classification for the diverse clinical spectrum of X-ALD.
  • To review the current understanding of X-ALD's largely unresolved pathophysiological mechanisms.
  • To summarize existing treatment options for X-ALD patients.

Main Methods:

  • Literature review of X-ALD pathophysiology and clinical presentations.
  • Analysis of existing classification systems for X-ALD.
  • Synthesis of current therapeutic strategies for X-ALD.

Main Results:

  • X-ALD exhibits significant clinical heterogeneity, primarily affecting males with adrenocortical insufficiency, myelopathy, and neuropathy.
  • A subset of males develops fatal cerebral demyelination (cerebral X-ALD).
  • Females typically experience milder symptoms, mainly myelopathy and neuropathy, at a later age.

Conclusions:

  • A simplified classification system for X-ALD is proposed.
  • Pathophysiological mechanisms underlying X-ALD remain incompletely understood.
  • Current treatment options for X-ALD are discussed, highlighting the need for further research.